David Hoang
Stock Analyst at Deutsche Bank
(3.87)
# 868
Out of 5,182 analysts
50
Total ratings
50%
Success rate
12.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $55 → $88 | $75.05 | +17.26% | 2 | Apr 14, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $12 | $4.03 | +197.77% | 1 | Mar 27, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $56 → $90 | $56.44 | +59.46% | 4 | Mar 10, 2026 | |
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $83.03 | +24.05% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $34.99 | +28.61% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $330.02 | -15.16% | 2 | Oct 17, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $30.99 | +16.17% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $19.96 | -39.86% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $22.40 | +56.25% | 5 | May 21, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $19.62 | +58.00% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $9.86 | +559.23% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $217.38 | -19.04% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $152.25 | +3.78% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.56 | +173.44% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.27 | +120.08% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.05 | +295.06% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $295.05 | -25.44% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $72.69 | +10.06% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.33 | +817.43% | 1 | Dec 7, 2022 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $55 → $88
Current: $75.05
Upside: +17.26%
AtaiBeckley
Mar 27, 2026
Initiates: Buy
Price Target: $12
Current: $4.03
Upside: +197.77%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $56 → $90
Current: $56.44
Upside: +59.46%
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $83.03
Upside: +24.05%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $34.99
Upside: +28.61%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $330.02
Upside: -15.16%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $30.99
Upside: +16.17%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $19.96
Upside: -39.86%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $22.40
Upside: +56.25%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $19.62
Upside: +58.00%
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $9.86
Upside: +559.23%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $217.38
Upside: -19.04%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $152.25
Upside: +3.78%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.56
Upside: +173.44%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $7.27
Upside: +120.08%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.05
Upside: +295.06%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $295.05
Upside: -25.44%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $72.69
Upside: +10.06%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.33
Upside: +817.43%